A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Cascadian Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT01983501
First received: October 28, 2013
Last updated: April 7, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2016
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)